BiotechTube
Home/Pipeline/NLRP3 Inhibitor

NLRP3 Inhibitor

Cardiovascular Disease

Phase 1Active

Key Facts

Indication
Cardiovascular Disease
Phase
Phase 1
Status
Active
Company
Novo Nordisk

About Novo Nordisk

Novo Nordisk's mission is to defeat diabetes and other serious chronic diseases through innovative biopharmaceutical solutions. The company has achieved transformative success with its GLP-1-based therapies, Ozempic® and Wegovy®, catalyzing a new era in metabolic care and generating massive commercial growth. Its strategy is built on expanding the clinical utility of its core platforms, advancing a deep pipeline of next-generation multi-agonists and novel modalities, and scaling manufacturing to meet global demand. Recent milestones include the US approval of the first once-weekly basal insulin, Awiqli®, and promising Phase 2 data for a triple agonist.

View full company profile

Therapeutic Areas

DiabetesObesityRare Blood & Endocrine DisordersCardiovascular DiseaseChronic Kidney Disease

Other Cardiovascular Disease Drugs

DrugCompanyPhase
Manocept DiagnosticNavidea BiopharmaceuticalsResearch
Undisclosed Therapeutic Program(s)HeartcoR SolutionsPre-clinical
Ramatroban (KAR101)KARE BiosciencesPreclinical
Undisclosed Cardiovascular Device ProgramTransluminal TechnologiesPre-clinical
iPSC-CM Cell TherapyKhloris BiosciencesResearch
Clinical Trial IntegrationAktiiaVarious
Cardiovascular Disease StudyArizona Research CenterNot Specified
Cardiovascular Clinical TrialsPanThera BioNot Specified
UndisclosedZecardio TherapeuticsDiscovery/Pre-clinical
HDL/LDL RegulationAlpha-1 BiologicsPre-clinical
Cardiovascular ProgramHelixomerResearch
Undisclosed Cardiovascular PrograminQB8 Medical TechnologiesPre-clinical